{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+II&page=87", "query": { "intervention": "Control II", "page": 87 }, "page_size": 10 }, "pagination": { "page": 87, "page_size": 10, "total_count": 2669, "total_pages": 267, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+II&page=88&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+II&page=86&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-02T11:30:03.756Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04952753", "title": "Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "NIS793", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Modified FOLFOX6", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 204, "start_date": "2021-11-15", "completion_date": "2025-01-20", "has_results": false, "last_update_posted_date": "2025-03-26", "last_synced_at": "2026-11-02T11:30:03.756Z", "location_count": 7, "location_summary": "Los Angeles, California • Ann Arbor, Michigan • St Louis, Missouri + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "East Brunswick", "state": "New Jersey" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04952753" }, { "nct_id": "NCT05067595", "title": "Fecal Microbiota Transplant and Dietary Fiber Supplementation for the Treatment of Gut Graft Versus Host Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Intestinal Graft Versus Host Disease" ], "interventions": [ { "name": "Colonoscopy", "type": "PROCEDURE" }, { "name": "Fecal Microbiota Transplantation", "type": "BIOLOGICAL" }, { "name": "Nutritional Supplementation", "type": "DIETARY_SUPPLEMENT" }, { "name": "Survey Administration", "type": "OTHER" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DIETARY_SUPPLEMENT", "OTHER" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2025-01-24", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-11-02T11:30:03.756Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05067595" }, { "nct_id": "NCT01484639", "title": "Transfusion Requirements in Cardiac Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cardiac Surgery" ], "interventions": [ { "name": "Liberal transfusion triggers", "type": "OTHER" }, { "name": "Restrictive transfusion triggers", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Nadine Shehata", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 208, "start_date": "2012-01", "completion_date": "2012-11", "has_results": false, "last_update_posted_date": "2013-02-21", "last_synced_at": "2026-11-02T11:30:03.756Z", "location_count": 1, "location_summary": "Richmond, Virginia", "locations": [ { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01484639" }, { "nct_id": "NCT00736645", "title": "Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "selenomethionine", "type": "DIETARY_SUPPLEMENT" }, { "name": "finasteride", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG", "OTHER" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 55, "start_date": "2008-08", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2023-10-02", "last_synced_at": "2026-11-02T11:30:03.756Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00736645" }, { "nct_id": "NCT01150695", "title": "Phase II Tularemia Vaccine Comparison", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Tularaemia" ], "interventions": [ { "name": "Placebo", "type": "OTHER" }, { "name": "Undiluted Francisella tularensis live attenuated vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 228, "start_date": "2010-09", "completion_date": "2012-01", "has_results": false, "last_update_posted_date": "2016-01-13", "last_synced_at": "2026-11-02T11:30:03.756Z", "location_count": 5, "location_summary": "Decatur, Georgia • Iowa City, Iowa • Baltimore, Maryland + 2 more", "locations": [ { "city": "Decatur", "state": "Georgia" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01150695" }, { "nct_id": "NCT00424931", "title": "A Safety and Effectiveness Study of a Single Dose of JNJ-17216498 in Patients With Narcolepsy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Narcolepsy" ], "interventions": [ { "name": "JNJ-17216498", "type": "DRUG" }, { "name": "Modafinil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alza Corporation, DE, USA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 16, "start_date": "2007-01", "completion_date": "2007-12", "has_results": false, "last_update_posted_date": "2014-05-23", "last_synced_at": "2026-11-02T11:30:03.756Z", "location_count": 16, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00424931" }, { "nct_id": "NCT04237623", "title": "GM-CSF With Post-Transplant Cyclophosphamide", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Transplant-Related Hematologic Malignancy" ], "interventions": [ { "name": "Sargramostim", "type": "DRUG" }, { "name": "Control Arm", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Northside Hospital, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "78 Years", "sex": "ALL", "summary": "18 Years to 78 Years" }, "enrollment_count": 38, "start_date": "2020-05-18", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-11-02T11:30:03.756Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04237623" }, { "nct_id": "NCT01497223", "title": "MGCD290 and Fluconazole Versus Fluconazole Alone for the Treatment of Moderate to Severe Vulvovaginal Candidiasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Vulvovaginal Candidiasis" ], "interventions": [ { "name": "MGCD290", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MethylGene Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 220, "start_date": "2011-12", "completion_date": "2013-04", "has_results": false, "last_update_posted_date": "2013-04-04", "last_synced_at": "2026-11-02T11:30:03.756Z", "location_count": 19, "location_summary": "Birmingham, Alabama • San Diego, California • Lake Worth, Florida + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "Lake Worth", "state": "Florida" }, { "city": "North Miami", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01497223" }, { "nct_id": "NCT05769582", "title": "Safety, Tolerability and Efficacy of AntiBKV as Treatment of BKV Infection in Kidney Transplant Recipients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "BK Viremia; BKV DNAemia" ], "interventions": [ { "name": "Anti-BK polyomavirus (AntiBKV)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Memo Therapeutics AG", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 95, "start_date": "2023-04-10", "completion_date": "2025-07-15", "has_results": false, "last_update_posted_date": "2025-09-29", "last_synced_at": "2026-11-02T11:30:03.756Z", "location_count": 23, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05769582" }, { "nct_id": "NCT01498328", "title": "A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma", "Small Cell Glioblastoma", "Giant Cell Glioblastoma", "Gliosarcoma", "Glioblastoma With Oligodendroglial Component", "Recurrent Glioblastoma", "Relapsed Glioblastoma" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Rindopepimut (CDX-110) with GM-CSF", "type": "DRUG" }, { "name": "KLH", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 127, "start_date": "2011-12", "completion_date": "2016-05-17", "has_results": false, "last_update_posted_date": "2020-02-17", "last_synced_at": "2026-11-02T11:30:03.756Z", "location_count": 45, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 37 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01498328" } ] }